Puerarin inhibits inflammation and lipid accumulation in alcoholic liver disease through regulating MMP8.
- Author:
Ying HU
1
,
2
,
3
;
Shuxian WANG
1
,
2
,
3
;
Lan WU
1
,
2
,
3
;
Kai YANG
1
,
2
,
4
,
5
;
Fan YANG
6
;
Junfa YANG
1
,
2
,
3
;
Shuang HU
1
,
2
,
3
;
Yan YAO
1
,
2
,
3
;
Xun XIA
1
,
2
,
3
;
Yixin LIU
1
,
2
,
3
;
Li PENG
1
,
2
,
3
;
Jihong WAN
1
,
2
,
3
;
Chuanpu SHEN
1
,
2
,
7
;
Tao XU
1
,
2
,
8
Author Information
- Publication Type:Journal Article
- Keywords: Alcoholic liver disease; Inflammatory; Lipid accumulation; MMP8; Puerarin
- From: Chinese Journal of Natural Medicines (English Ed.) 2023;21(9):670-681
- CountryChina
- Language:English
- Abstract: Alcoholic liver disease (ALD) is a growing global health concern, and its early pathogenesis includes steatosis and steatohepatitis. Inhibiting lipid accumulation and inflammation is a crucial step in relieving ALD. Evidence shows that puerarin (Pue), an isoflavone isolated from Pueraria lobata, exerts cardio-protective, neuroprotective, anti-inflammatory, antioxidant activities. However, the therapeutic potential of Pue on ALD remains unknown. In the study, both the NIAAA model and ethanol (EtOH)-induced AML-12 cell were used to explore the protective effect of Pue on alcoholic liver injury in vivo and in vitro and related mechanism. The results showed that Pue (100 mg·kg-1) attenuated EtOH-induced liver injury and inhibited the levels of SREBP-1c, TNF-α, IL-6 and IL-1β, compared with silymarin (Sil, 100 mg·kg-1). In vitro results were consistent within vivo results. Mechanistically, Pue might suppress liver lipid accumulation and inflammation by regulating MMP8. In conclusion, Pue might be a promising clinical candidate for ALD treatment.